Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VNRX-5024 in healthy volunteers
NCT04314206Phase 1Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Jul 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing VNRX-5024 with Placebo (2 arms). Primary endpoint: Adverse Events at 19 days. Started Jul 2020; status: completed.
02
Drugs
VNRX-5024
Beyond the preview
Go deeper on NCT04314206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04314206.